T-cell receptor therapy safe, effective for soft tissue sarcoma

CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft tissue sarcoma, according to results from a phase 1 study presented at ASCO Annual Meeting.
Investigators said early data from the study suggest the treatment is safe and tolerable.
TAEST16001 is an investigational autologous T-cell therapy genetically engineered to express a high-affinity T-cell receptor that targets the cancer-testis antigen NY-ESO-1.
“Soft tissue sarcoma is known to express high levels of NY-ESO-1, making it a promising target for this novel cellular therapy,”

CHICAGO — A novel T-cell receptor therapy showed promising antitumor activity in patients with advanced soft tissue sarcoma, according to results from a phase 1 study presented at ASCO Annual Meeting.
Investigators said early data from the study suggest the treatment is safe and tolerable.
TAEST16001 is an investigational autologous T-cell therapy genetically engineered to express a high-affinity T-cell receptor that targets the cancer-testis antigen NY-ESO-1.
“Soft tissue sarcoma is known to express high levels of NY-ESO-1, making it a promising target for this novel cellular therapy,”